Clinical TrialMay 31, 2026, 07:31 PM
Ascentage Pharma's Alrizomadlin Shows Promising Pediatric Solid Tumor Data at ASCO
AI Summary
Ascentage Pharma presented its first dataset of alrizomadlin (APG-115) as monotherapy or in combination with lisaftoclax (APG-2575) in pediatric patients with relapsed/metastatic rhabdomyosarcoma or other soft-tissue sarcomas at the ASCO Annual Meeting. The data demonstrated preliminary antitumor activity and a manageable tolerability profile, including one complete response with monotherapy and an objective response rate of 23.5% in the combination arm. Alrizomadlin has also been included in China's "SPARK Plan" for pediatric solid tumors, highlighting its potential as a first-in-class therapy.
Key Highlights
- Alrizomadlin monotherapy achieved one complete response (CR) in a pediatric rhabdomyosarcoma patient.
- The combination of alrizomadlin and lisaftoclax showed an objective response rate (ORR) of 23.5% among 17 evaluable patients.
- The combination arm included one complete response in an Ewing sarcoma patient and three partial responses.
- The disease control rate (DCR) for the combination arm was 70.6%.
- Alrizomadlin, as monotherapy or in combination, demonstrated a manageable safety profile in pediatric patients.
- No dose-limiting toxicities (DLTs) were observed in either treatment arm.
- Alrizomadlin was included in China's "SPARK Plan" for pediatric solid tumors.
Price Impact
More from AAPG